Pembrolizumab in Metastatic Anal Cancer

Status Completed

Clinical Trial Summary

This research study is studying a targeted therapy as a possible treatment for advanced anal cancer. The following intervention will be involved in this study: -Pembrolizumab

Clinical Trial Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab for Advanced Anal Cancer, but it has been approved for other uses. Pembrolizumab, also known as KEYTRUDA or MK-3475, is approved in the USA and several other countries to treat a type of skin cancer called Malignant Melanoma. In this research study the investigators are studying an investigational drug called Pembrolizumab, which is a monoclonal antibody. Monoclonal antibodies are manmade and mimic proteins in the immune system by attaching to specific proteins in the body. T cells are cells in the immune system that are controlled by PD-1. PD-1 is a protein on the T cells that prevent the body from overproducing T cells. Pembrolizumab targets PD-1, attaches to it and blocks its action. By preventing PD-1 from working, T cell production rises and the body's immune system may increase its action against Cancer cells. Clinical and laboratory studies using pembrolizumab suggest that pembrolizumab may be useful in shrinking certain tumors. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02919969
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Completed
Phase	Phase 2
Start date	October 11, 2016
Completion date	March 2023

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05060471` - PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients	Phase 2
Active, not recruiting	`NCT02135419` - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions	Phase 3
Completed	`NCT05518201` - Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old	Phase 1
Withdrawn	`NCT02857608` - A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus	Phase 2
Active, not recruiting	`NCT02546973` - Quality of Life in Patients With Anal Cancer
Terminated	`NCT00903396` - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer	Phase 2
Terminated	`NCT00896467` - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy	N/A
Completed	`NCT00550589` - Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus	Phase 2
Completed	`NCT00324415` - Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer	Phase 2
Terminated	`NCT00568425` - QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
Terminated	`NCT00267787` - Molecular Genetic and Pathological Studies of Anal Tumors
Completed	`NCT00066430` - Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia	Phase 1
Completed	`NCT04083053` - High-Resolution Anoscopy Perceived Discomfort Study	N/A
Completed	`NCT03506529` - Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT
Recruiting	`NCT05835947` - Anal Cancer Risk In Women
Not yet recruiting	`NCT03947775` - HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL	Phase 2
Recruiting	`NCT04857528` - Detecting HPV DNA in Anal and Cervical Cancers
Recruiting	`NCT04907643` - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	N/A
Recruiting	`NCT04708470` - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers	Phase 1/Phase 2
Active, not recruiting	`NCT01937780` - Anal Cancer Radiotherapy Study